Baidu
map

JACC:房颤患者发生脑淀粉样血管病 管理策略出新招

2017-10-10 王立群 环球医学

2017年8月,发表在《J Am Coll Cardiol》的一项由美国科学家进行的研究,考察了房颤患者发生脑淀粉样血管病的诊断、临床意义和管理策略。

2017年8月,发表在《J Am Coll Cardiol》的一项由美国科学家进行的研究,考察了房颤患者发生脑淀粉样血管病的诊断临床意义和管理策略。

随着人口老龄化,医生更经常遇见房颤患者也处于脑淀粉样血管病造成脑血管中β淀粉样蛋白沉积,进而造成颅内出血的风险。脑淀粉样血管病在老年患者中常见,与颅内出血风险的增加相关,尤其是使用抗凝药时。尽管具有该相关性,但是其在目前的风险获益模型中并不存在,这会低估患有该疾病的患者的出血几率。当颅内出血后计划开始或重新开始抗凝治疗时,确定脑淀粉样血管病的存在与负担尤其重要。鉴于缺乏随机试验数据指导管理策略,研究人员讨论了一种心-脑团队方法,该方法纳入了医生患者共同决策,确定是否使用药物和非药物方法来减少卒中风险。
 
原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-04-03 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-08-23 gous
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1853799, encodeId=ab3a1853e9960, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 03 13:34:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046659, encodeId=9d6220466595d, content=<a href='/topic/show?id=9b708491280' target=_blank style='color:#2F92EE;'>#脑淀粉样#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84912, encryptionId=9b708491280, topicName=脑淀粉样)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Tue Feb 27 10:34:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1966944, encodeId=73f519669444a, content=<a href='/topic/show?id=b5bde60540a' target=_blank style='color:#2F92EE;'>#管理策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76054, encryptionId=b5bde60540a, topicName=管理策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Aug 23 06:34:00 CST 2018, time=2018-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644602, encodeId=d778164460265, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Dec 06 16:34:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325552, encodeId=aff8132555241, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614401, encodeId=7acc161440140, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628772, encodeId=64691628e72ef, content=<a href='/topic/show?id=1c748491616' target=_blank style='color:#2F92EE;'>#脑淀粉样血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84916, encryptionId=1c748491616, topicName=脑淀粉样血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac7921195890, createdName=Smile2687, createdTime=Thu Oct 12 08:34:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]

相关资讯

Ann Med:荟萃分析显示CHADS2和CHA2DS2-VASc评分对非房颤患者卒中发生的诊断性良好

目的:CHA2DS2-VASc是伯明翰2009开发的CHADS2评分的延伸。在临床上当考虑房颤患者卒中发生额外的风险时,用此评分进行风险分层。然而,它在非房颤的人口中的作用是尚不清楚。本研究的目的是评估CHADS2 和CHA2DS2-VASc评分系统的准确性。方法:纳入CHADS2和CHA2DS2-VASc评分对非房颤患者卒中发生的风险分层的研究。结果: 在选出的114项研究中,最终选择了六个试验

JACC:房颤患者使用达比加群2年内依从性如何?

2017年9月,发表在《J Am Coll Cardiol》上的一项研究,调查了房颤患者在2年的随访期中对达比加群酯依从性。研究结果显示:2年后,达比加群治疗依从的概率约为70%。近一半停用达比加群的患者转换为另一种口服抗凝药。并且北美患者和具有阵发性、持续性或症状性房颤的患者具有较高的停止达比加群风险。

Am Heart J:哪些房颤患者更愿意选择NOAC预防卒中?

非维生素K拮抗剂口服抗凝剂(NOAC)的问世,让房颤(AF)患者预防卒中有了多样化的选择。2017年7月,发表在《Am Heart J》的一项研究显示,高达四分之三的新发AF患者初始选用NOAC预防卒中。选择NOAC治疗的患者总体卒中和出血风险较低,更可能由心脏病专家治疗,并且具有较高的社会经济地位。

ESC2017重磅研究万众瞩目:RE-DUALPCI研究 房颤患者冠脉介入术后抗凝策略将有重大突破?

2周后,2017年欧洲心脏病学会(ESC)年会就要召开了,会上将要公布一项万众瞩目的研究:RE-DUALPCI?,该研究的目的是,对于房颤患者,在冠状动脉介入治疗(PCI)术后比较达比加群联合P2Y12抑制剂双抗,是否优于华法林联合双联抗血小板治疗?

ESC 2014:如何在全科实践中识别新发房颤?(PROFIL FA研究)

来自法国的戴维(Jean-Marc Davy)教授在本次ESC年会上作了“在全科医学实践中识别新发房颤的简单认识运动”(PROFIL FA研究)的报告。戴维教授说:“房颤是最常见的心律失常。房颤使心衰风险升高3倍、卒中风险升高5倍;1/4的缺血性卒中患者病因是房颤。但是,房颤经常被忽略,确诊较晚。20%的病例是由于发生了卒中后才确诊有房颤。为此,我们发起了一项运动以改进房颤的早期诊断。”

ACC2017:RE-CIRCUIT研究:房颤患者导管消融围手术期不间断使用泰毕全较华法林大出血显著减少

在2017年ACC年会上公布的RE-CIRCUIT研究让人眼前一亮,该研究结果表明,房颤患者在导管消融围手术期间不间断使用泰毕全(达比加群酯)更为安全,大出血和严重不良反应事件均显着减少[1]。这一研究结果同时也在《新英格兰杂志》刊登[2]。

Baidu
map
Baidu
map
Baidu
map